GET DAILY SIGNALSTELA Bio (TELA) Analysts See +133% Upside to $2 Target After Leadership Refresh
Key Takeaways
- The central $2 price target is the arithmetic mean of five verified analyst price targets, which range from $1.00 to $3.00.
- With shares recently trading near $0.86, reaching $2 would require roughly 133% upside — a very large move from current levels.
- Coverage skews positive, with four Buy ratings and one Hold (Piper Sandler's $1 target) among the firms reviewed.
- Key supports include a refreshed leadership team, expanding OviTex procedure adoption, and regained Nasdaq listing compliance.
- Principal risks are persistent cash burn, negative stockholders' equity, withdrawn full-year guidance, and continued weakness in the PRS (plastic and reconstructive surgery) product line.
- Explore Major News, Today's Price Move, the Forecast page, and Earnings for additional detail on this ticker.
- For automated ideas across the market, explore Trending AI Robots.
Analyst Price Targets and Consensus View
TELA Bio, Inc. (TELA) is a commercial-stage medical technology company based in Malvern, Pennsylvania, focused on soft-tissue reconstruction products such as OviTex and OviTex PRS used primarily in hernia repair. It is a stock, not an exchange-traded fund.
A review of recent analyst coverage identified five attributable price targets: Canaccord Genuity at $2.00 (Buy), Lake Street at $2.00 (Buy), Craig-Hallum at $2.00 (Buy), Piper Sandler at $1.00 (Hold), and Citizens JMP at $3.00 (Buy, lowered from $5.00 in March 2026). The arithmetic mean of these five targets is $2.00, with an unusually wide range of $1.00 to $3.00.
This spread reflects genuine disagreement. Bulls such as Craig-Hallum argue that the June 2026 board refresh — including Chairman Joe Capper and CEO Heather Getz, who previously helped lead BioTelemetry from a small-cap to a multi-billion-dollar sale — could reignite mid-teens revenue growth and justify a higher valuation. More cautious analysts, including Piper Sandler, want proof of execution and a clearer path to breakeven before assigning greater upside. The $2 mean should be read as a directional benchmark, not a guarantee. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Current Market Position and Path Toward the Target
TELA shares have been highly volatile, trading within a 52-week range of roughly $0.50 to $1.50. After briefly trading near $0.94 in November 2026, the stock pulled back to about $0.86 in subsequent sessions, leaving the company with a market capitalization around $40 million and shares in sub-$1 "penny stock" territory.
Moving from $0.86 to $2.00 implies upside of approximately 133%, which qualifies as a very large move. That path would most plausibly require the company to demonstrate a durable return to revenue growth, rebuild confidence in the PRS franchise, and show meaningful progress toward cash-flow breakeven — developments that could also address the depressed valuation currently applied to the shares.
What Could Support a Move Toward the Target
Several verified factors could support a re-rating. TELA's OviTex platform continues to expand surgeon adoption, and the company has reported year-over-year growth in its U.S. hernia portfolio unit volume, along with continued growth in Europe. A new product, the fully resorbable Liora scaffold, received FDA 510(k) clearance, and the LIQUIFIX fixation line posted a record quarter of sales.
Operationally, management launched a roughly $17 million cost-reduction program designed to narrow cash burn while preserving growth investment. The company also announced in October 2026 that it had regained compliance with Nasdaq's minimum bid price requirement, reducing near-term delisting uncertainty. The refreshed leadership team and a $70 million Perceptive Credit term loan facility (with an initial $60 million drawn) provide additional financial runway and strategic optionality.
What Could Prevent the Target From Being Reached
The obstacles are substantial. TELA is not yet profitable and carries negative stockholders' equity alongside elevated debt, leaving it dependent on financing and cost discipline. Management withdrew full-year guidance amid a commercial reorganization, and the PRS segment has contracted sharply, with longer sales-representative ramp times weighing on visibility.
The stock's sub-$1 level itself creates structural risks, including potential future delisting concerns, limited institutional participation, and dilution from equity raises. A $2 target implies roughly a doubling-plus move, which would demand a level of sustained execution the company has not yet demonstrated, making downside to a Hold-style $1 objective a meaningful risk.
Technical Levels and Market Structure
Technically, TELA sits in a difficult zone. The $1.00 level acts as both a psychological threshold and a near-term resistance area, roughly matching Piper Sandler's target. Above that, the stock's recent highs near $1.50 and the 52-week peak around $1.50–$1.60 represent the next major resistance zones on the way toward $2.00. On the downside, the 52-week low near $0.50 serves as a key support reference. The wide intraday swings and thin float mean price moves can be outsized relative to fundamental news.
Time Horizon and What Investors Should Monitor
Analyst price targets generally reflect a research horizon of about 12 months, though the exact timeframe varies by firm and was not uniformly disclosed. Investors should watch quarterly results for evidence of PRS stabilization and hernia growth, any reinstated or updated full-year guidance, cash-burn trajectory, analyst rating or target revisions, and Nasdaq listing-status updates. Financing activity and Liora's commercialization plan, expected in early 2027, are also key variables. From what I see, reviewing signals with Tickeron’s AI Daily Buy/Sell Signals helps track these developments systematically.
Final Assessment
The $2 central target — the mean of five analyst price targets spanning $1.00 to $3.00 — would require roughly a 133% advance from TELA's recent price near $0.86, an objectively very large move. The bull case rests on refreshed leadership, expanding OviTex adoption, new product clearances, and regained Nasdaq compliance. The bear case is anchored in ongoing losses, negative equity, withdrawn guidance, and PRS weakness. The wide target range underscores genuine analyst disagreement. Whether TELA can reach $2 depends primarily on whether management can convert its commercial reset into sustained, profitable growth — a question the coming quarterly reports and any guidance updates will begin to answer.
Using AI Daily Buy/Sell Signals for TELA
Traders seeking a systematic view can turn to Tickeron's AI Daily Buy/Sell Signals. The platform uses artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. For a volatile, low-priced stock such as TELA, these signals can help traders spot shifting trends and manage positions more efficiently than manual screening alone. I find this approach useful when reviewing names like TELA alongside my own fundamental work.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
TELA in upward trend: price expected to rise as it breaks its lower Bollinger Band on October 30, 2026
TELA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 36 of 44 cases where TELA's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 82%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where TELA's RSI Oscillator exited the oversold zone, 25 of 32 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 78%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 48 of 67 cases where TELA's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 72%.
The Moving Average Convergence Divergence (MACD) for TELA just turned positive on November 12, 2026. Looking at past instances where TELA's MACD turned positive, the stock continued to rise in 29 of 43 cases over the following month. The odds of a continued upward trend are 67%.
Following a +10.85% 3-day Advance, the price is estimated to grow further. Considering data from situations where TELA advanced for three days, in 182 of 236 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 22, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on TELA as a result. In 89 of 101 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 88%.
TELA moved below its 50-day moving average on October 23, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for TELA crossed bearishly below the 50-day moving average on October 29, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TELA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
The Aroon Indicator for TELA entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 26 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-2.333) is normal, around the industry mean (4.142). P/E Ratio (-1.065) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (0.782) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 50 (best 1 - 100 worst), indicating steady price growth. TELA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 62 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TELA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a commercial stage medical technology company, which focuses on designing, developing and marketing of tissue reinforcement materials to address unmet needs in soft tissue reconstruction.
Industry MedicalNursingServices
Advertisement